Experts and Doctors on antineoplastic agents in Lyon, Auvergne Rhône Alpes, France


Locale: Lyon, Auvergne Rhône Alpes, France
Topic: antineoplastic agents

Top Publications

  1. Aouacheria A. Novel genetic and peptide-based strategies targeting the Bcl-2 family, an update. Recent Pat DNA Gene Seq. 2009;3:123-9 pubmed
    ..This paper provides a brief review of the most recent patents that have been published relating to this area. ..
  2. Jordheim L, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12:447-64 pubmed publisher
    ..We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy. ..
  3. Cassier P, Gelderblom H, Stacchiotti S, Thomas D, Maki R, Kroep J, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118:1649-55 pubmed publisher
    ..The authors concluded that the benefits of alleviating morbidity in patients with localized PVNS/TGCT must be balanced against the potential toxicity of chronic drug therapy. ..
  4. Dizin E, Ray H, Suau F, Voeltzel T, Dalla Venezia N. Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis. Apoptosis. 2008;13:237-46 pubmed
    ..The data presented here provide new insight into the role of endogenous BRCA1 as a mediator of apoptosis and show that BRCA1 functions as a molecular determinant of response to a range of cytotoxic chemotherapeutic agents. ..
  5. Berry V, Basson L, Bogart E, Mir O, Blay J, Italiano A, et al. REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017;123:2294-2302 pubmed publisher
  6. Galmarini C, Kamath K, Vanier Viornery A, Hervieu V, Peiller E, Falette N, et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer. 2003;88:1793-9 pubmed
    ..We conclude that p53 protein may contribute to the regulation of microtubule composition and function, and that alterations in p53 function may generate complex microtubule-associated mechanisms of resistance to tubulin-binding agents. ..
  7. Blay J, Le Cesne A, Cassier P, Ray Coquard I. Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med. 2012;13:357-67 pubmed
    ..For this aspect also, GIST is again a paradigmatic model for oncology, as many tumors with a higher prevalence will be fragmented in different molecular subsets and are going to become rare disease in the years to come. ..
  8. Claude L, Schell M. [Hodgkin's disease: treatment specificities in childhood]. Cancer Radiother. 2009;13:527-9 pubmed publisher
    ..In this article, we focus on the paediatric particularities, especially in term of current treatment strategy. The aim is to decrease the important rate of late effects while keeping the excellent survival. ..
  9. Angevin E, Cassier P, Italiano A, Goncalves A, Gazzah A, Terret C, et al. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. Eur J Cancer. 2017;83:194-202 pubmed publisher
    ..Addition of LY2780301 to gemcitabine showed manageable toxicity and encouraging antitumour activity in patients with molecular alterations of the PI3K/AKT/mTOR pathway. NCT02018874. ..

More Information


  1. Zhang A, Judson I, Benson C, Wunder J, Ray Coquard I, Grimer R, et al. Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. Br J Cancer. 2017;117:326-331 pubmed publisher
    ..Anthracyclines and alkylating agents significantly contribute to the effect. This study confirms an association between chemotherapy given for the first malignancy and a shorter time to development of RIS. ..
  2. Cassier P, Dufresne A, Fayette J, Alberti L, Ranchere D, Ray Coquard I, et al. Emerging drugs for the treatment of soft tissue sarcomas. Expert Opin Emerg Drugs. 2007;12:139-53 pubmed
    ..This review summarises treatment strategies in the context of advanced disease and discusses new compounds being developed for patients with soft tissue sarcomas. ..
  3. Broutier L, Creveaux M, Vial J, Tortereau A, Delcros J, Chazot G, et al. Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas. EMBO Mol Med. 2016;8:96-104 pubmed publisher
    ..Together, these data suggest that interference with the netrin-1/DCC interaction could represent a promising therapeutic strategy in netrin-1-positive DLBCL and MCL. ..
  4. Imbs D, Paludetto M, Négrier S, Powell H, Lafont T, White Koning M, et al. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. Invest New Drugs. 2016;34:41-8 pubmed publisher
    ..Variable albumin concentrations, frequently observed in cancer patients, may affect pazopanib unbound fraction with implications for inter-patient variability in drug efficacy and toxicity. ..
  5. Ruszniewski P, Valle J, Lombard Bohas C, Cuthbertson D, Perros P, Holubec L, et al. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis. 2016;48:552-558 pubmed publisher
    ..Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome ( NCT01234168). ..
  6. Dalle S, Martin Denavit T, Thomas L. [Genotypic hypervariability of melanoma: a therapeutic challenge]. Med Sci (Paris). 2006;22:178-82 pubmed
    ..It is hope that this better understanding of the biologic features of melanoma and the mechanisms underlying tumor-induced immunosuppression will lead to efficaceous targeted therapy. ..
  7. Hadji P, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27:379-90 pubmed publisher
  8. Pouliquen D, Olivier C, Hervouet E, Pedelaborde F, Debien E, Le Cabellec M, et al. Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis. Int J Cancer. 2008;123:288-295 pubmed publisher
    ..These results show that the degree of agressiveness of gliomas can be modulated by dietary interventions and suggest that some phytochemicals with antioxidant properties could participate to the mechanism. ..
  9. Galmarini C, Mackey J, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3:415-24 pubmed
    ..Strategies to optimise intracellular analogue accumulation and to enhance cancer-cell selectivity are proving beneficial in clinical trials. ..
  10. Derbel O, Zrounba P, Chassagne Clement C, Decouvelaere A, Orlandini F, Duplomb S, et al. An unusual giant cell tumor of the thyroid: case report and review of the literature. J Clin Endocrinol Metab. 2013;98:1-6 pubmed publisher
    ..Denosumab emerges as a new treatment for patients with GCTs. Additional clinical trial data are needed to establish the real efficacy and long-term safety of this treatment for the management of GCT. ..
  11. Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, et al. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology. 2013;97:331-40 pubmed publisher
    ..Our experimental data suggest that mTOR inhibition could be considered a therapeutic option for high-grade gastroenteropancreatic neuroendocrine tumors. ..
  12. Pivot X, Fumoleau P, Pierga J, Delaloge S, Bonnefoi H, Bachelot T, et al. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. Eur J Cancer. 2017;81:151-160 pubmed publisher
  13. Blay J, Ray Coquard I, Alberti L, Ranchere D. Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas. Cancer Treat Res. 2004;120:151-67 pubmed
  14. Le Saux O, Freyer G, Négrier S. First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review. Clin Drug Investig. 2016;36:389-99 pubmed publisher
    ..The upcoming challenge is to discover more effective new drugs since the overall survival of poor-prognosis mRCC still remains extremely limited. ..
  15. Brandt A, Gozzi G, Pires A, Martinez G, Dos Santos Canuto A, Echevarria A, et al. Impairment of oxidative phosphorylation increases the toxicity of SYD-1 on hepatocarcinoma cells (HepG2). Chem Biol Interact. 2016;256:154-60 pubmed publisher
    ..Therefore, we may propose that SYD-1 is a potential candidate for hepatocarcinoma treatment. ..
  16. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer. 2008;16:1017-23 pubmed publisher
  17. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol. 2010;5:S291-5 pubmed publisher
    ..Given the rarity of these tumors, translation of preclinical findings to the clinic may be quick and represents one of the most promising therapeutic approaches for advanced-stage thymic malignancies. ..
  18. Nishida T, Blay J, Hirota S, Kitagawa Y, Kang Y. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3-14 pubmed publisher
    ..This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. ..
  19. Ray Coquard I, Morere J, Scotte F, Cals L, Antoine E. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey. Adv Ther. 2012;29:124-33 pubmed publisher
    ..Overall, the management of chemotherapy-induced anemia was improved compared with what was described in the historical surveys (European Cancer Anaemia Survey [ECAS], French Anaemia Cancer Treatment [F-ACT]). ..
  20. Coiffier B, Altman A, Pui C, Younes A, Cairo M. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-78 pubmed publisher
    ..These guidelines should assist in the prevention of TLS and improve the management of patients with established TLS. ..
  21. Thomas X. Emerging drugs for adult acute lymphoblastic leukaemia. Expert Opin Emerg Drugs. 2005;10:591-617 pubmed
    ..With a better understanding of the disease, more target-specific therapies could be designed. The aim of this review is to highlight new pharmacotherapies and those emerging drug treatments for patients with adult ALL. ..
  22. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer. 2008;7:50 pubmed publisher
    ..This study opens the way to further clinical investigations and suggests a potential benefit of using a combination of bortezomib with an inhibitor of p38 MAPK for the treatment of neuroblastoma relapse. ..
  23. Walter T, Hommell Fontaine J, Gouysse G, Pourreyron C, Nejjari M, Villaume K, et al. Effects of somatostatin and octreotide on the interactions between neoplastic gastroenteropancreatic endocrine cells and endothelial cells: a comparison between in vitro and in vivo properties. Neuroendocrinology. 2011;94:200-8 pubmed publisher
    ..The in vitro antiangiogenic effects of somatostatin and its analogues are likely to be efficiently counterbalanced in the tumor microenvironment by the concomitant release of proangiogenic factors like VEGF. ..
  24. Thomas X, Cannas G, Chelghoum Y, Gougounon A. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]. Bull Cancer. 2010;97:1105-17 pubmed publisher
    ..Advantages of these therapeutic alternatives to native L-asparaginase and their results as part of preliminary clinical trials in adults have been outlined in this review. ..
  25. Arifi S, El Sayadi H, Dufresne A, Ray Coquard I, Fayette J, Meeus P, et al. [Imatinib and solid tumours]. Bull Cancer. 2008;95:99-106 pubmed publisher
    ..We review the current data regarding the activity of imatinib in solid tumors, including GIST. ..
  26. Ray Coquard I, Cropet C, van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383-91 pubmed publisher
    ..48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers...
  27. Ray Coquard I, Blay J, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133-40 pubmed publisher
    ..We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection...
  28. Perez J, Bardin C, Rigal C, Anthony B, Rousseau R, Dutour A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 2011;31:2813-20 pubmed
    ..01). These results suggest the potential clinical application of anti-MDR1 siRNA to restore chemosensitivity and possibly improve the therapeutic ratio of these cytotoxic drugs. ..
  29. Duffaud F, Meeus P, Bertucci F, Delhorme J, Stoeckle E, Isambert N, et al. Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG). Eur J Surg Oncol. 2017;43:1110-1116 pubmed publisher
    ..Preoperative IM therapy could improve resectability and should be considered if surgery is contraindicated or would lead to negative impact on the functional status of the patient. ..
  30. Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315-337 pubmed publisher
  31. Beghin A, Matera E, Brunet Manquat S, Dumontet C. Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle. 2008;7:3074-82 pubmed
    ..Certain forms of phosphorylated p53 demonstrating increased binding to microtubules appear to be less prone to nuclear translocation after exposure to chemotherapeutic agents, thereby possibly contributing to reduced chemosensitivity. ..
  32. Blay J. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol. 2010;21:208-15 pubmed publisher
  33. Duez A, Cotte E, Glehen O, Cotton F, Bakrin N. Appraisal of peritoneal cavity's capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy. Surg Radiol Anat. 2009;31:573-8 pubmed publisher
    ..749, 0.348 and 0.644, respectively. The peritoneal cavity's capacity is mainly correlated with weight and the interest to assess the volume of liver and spleen remains questionable in terms of results. ..
  34. Wendtner C, Hallek M, Fraser G, Michallet A, Hillmen P, Dürig J, et al. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57:1291-9 pubmed publisher
    ..Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL. ..
  35. Lievre A, Artru P, Guiu M, Laurent Puig P, Merlin J, Sabourin J, et al. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. Eur J Cancer. 2013;49:2126-33 pubmed publisher
    ..This study confirmed that KRAS testing is definitely part of the management of most of mCRC patients, despite discrepancies observed in the rate of prescription and the time of results. ..
  36. Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, et al. Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. EMBO Mol Med. 2013;5:1821-34 pubmed publisher
    ..Together these data suggest that combining conventional chemotherapies with netrin-1 interference could be a promising therapeutic approach. ..
  37. Brose M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-28 pubmed publisher
    ..In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer...
  38. Wang Q, Moyret Lalle C, Couzon F, Surbiguet Clippe C, Saurin J, Lorca T, et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene. 2003;22:1486-90 pubmed
    ..Overall, these data support the hypothesis of a deleterious role of these mutations during colorectal carcinogenesis. ..
  39. Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130:1628-1638 pubmed publisher
    ..Collectively, our findings suggest HDAC6 inhibition is a rational therapeutic strategy to be implemented in combination therapies with anti-CD20 monoclonal antibodies and open up novel avenues for the clinical use of HDAC6 inhibitors. ..
  40. Krul I, Opstal van Winden A, Aleman B, Janus C, van Eggermond A, De Bruin M, et al. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. Int J Radiat Oncol Biol Phys. 2017;99:843-853 pubmed publisher
    ..HRT does not appear to increase BC risk for HL survivors with therapy-induced early menopause. There are no indications that endogenous and exogenous gonadal hormones affect the radiation dose-response relationship. ..
  41. Ray Coquard I, Italiano A, Bompas E, Le Cesne A, Robin Y, Chevreau C, et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17:260-6 pubmed publisher
    ..We investigated the antitumor activity of sorafenib in patients with metastatic or advanced angiosarcomas in a phase II trial...
  42. Catenoix H, Honnorat J, Cartalat Carel S, Chapuis F, Nighoghossian N, Trouillas P. [Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. Rev Neurol (Paris). 2006;162:1069-75 pubmed
    ..This treatment, of moderate toxicity, improves the quality of life and can result in long-term tumor stabilization. ..
  43. Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Michaud M, et al. [Multidrug resistance in uveal melanoma]. J Fr Ophtalmol. 2005;28:652-9 pubmed
    ..Indeed, we will have to know the genes to be targeted for each melanoma in order to induce cell chemosensitivity. ..
  44. Flechon A, Rivoire M, Droz J. Management of advanced germ-cell tumors of the testis. Nat Clin Pract Urol. 2008;5:262-76 pubmed publisher
    ..Owing to the complexity of treatment and the multidisciplinary approach required, patients with advanced germ-cell tumors should be managed in high-volume centers with experience of treating large numbers of patients. ..
  45. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, et al. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101:115-208 pubmed publisher
  46. Biron P, Durand M, Roche H, Delozier T, Battista C, Fargeot P, et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008;41:555-62 pubmed
    ..8) and 22.9 versus 22.3 months median time to relapse in the intensification and observation arms, respectively. In this randomized trial, HDC with CHUT improved DFS but not OS, corroborating findings from earlier trials. ..
  47. Valero J, Sancey L, Kucharczak J, Guillemin Y, Gimenez D, Prudent J, et al. Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells. J Cell Sci. 2011;124:556-64 pubmed publisher
    ..Thus, peptides derived from proteins that form pores in the mitochondrial outer membrane represent novel templates for anticancer agents. ..
  48. Marec Berard P, Azzi D, Chaux Bodard A, Lagrange H, Gourmet R, Bergeron C. Long-term effects of chemotherapy on dental status in children treated for nephroblastoma. Pediatr Hematol Oncol. 2005;22:581-8 pubmed
    ..These results indicate that chemotherapy in children may lead to troubles affecting teeth growing at the time of treatment. Information and prospective dental care are needed, and further investigations are required. ..
  49. Tod M, Mir O, Bancelin N, Coriat R, Thomas Schoemann A, Taieb F, et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res. 2011;28:3199-207 pubmed publisher
    ..In multivariate analysis, albuminemia (p?=?0.0036) was the single parameter independently associated with CL. These findings highlight the major influence of albuminemia on sorafenib clearance and its disposition in cancer patients. ..
  50. Seve P, Isaac S, Tredan O, Souquet P, Pacheco Y, Perol M, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 2005;11:5481-6 pubmed
    ..012). These findings suggest that a high level of expression of class III beta-tubulin in tumor cells is associated with resistance to vinorelbine and a poor prognosis in patients with NSCLC receiving vinorelbine-based chemotherapy. ..
  51. Cassier P, Fumagalli E, Rutkowski P, Schoffski P, van Glabbeke M, Debiec Rychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012;18:4458-64 pubmed
    ..Our data confirm that imatinib has little efficacy in the subgroup of patients with D842V substitution in exon 18, whereas other mutations appear to be sensitive to imatinib. ..
  52. Valdameri G, Pereira Rangel L, Spatafora C, Guitton J, Gauthier C, Arnaud O, et al. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem Biol. 2012;7:322-30 pubmed publisher
    ..We conclude that methoxy derivatives of stilbene are good candidates for investigating future in vivo modulation of ABCG2 drug-efflux activity. ..
  53. Pujade Lauraine E, Ledermann J, Selle F, Gebski V, Penson R, Oza A, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284 pubmed publisher
    ..Apart from anaemia, toxicities with olaparib were low grade and manageable. AstraZeneca. ..
  54. Valdameri G, Genoux Bastide E, Pérès B, Gauthier C, Guitton J, Terreux R, et al. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem. 2012;55:966-70 pubmed publisher
    ..The chromone derivative specifically inhibited ABCG2 versus other multidrug ABC transporters and was not transported. It constitutes a highly promising candidate for in vivo chemosensitization of ABCG2-expressing tumors. ..
  55. Harrington K, Ferris R, Blumenschein G, Colevas A, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104-1115 pubmed publisher
    ..Bristol-Myers Squibb. ..
  56. Droz J, Kramar A, Biron P, Pico J, Kerbrat P, Peny J, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol. 2007;51:739-46; discussion 747-8 pubmed
    ..This trial failed to demonstrate an impact on response and survival of high-dose chemotherapy with haematopoietic support in first-line treatment of patients with high-volume, metastatic nonseminomatous germ cell tumours. ..
  57. Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res. 2005;65:300-8 pubmed
    ..Such patients could benefit from a combination of androgen deprivation and antiangiogenic therapy in order to minimize the induction of such tumor escape. ..
  58. Galmarini C, Bouchet B, Falette N, Vila L, Lamblot C, Audoynaud C, et al. Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. Cancer Biol Ther. 2007;6:377-82 pubmed
    ..The present data therefore indicate an aneugenic potential of paclitaxel for humans, which should be considered in the risk-benefit analysis of its increasing clinical use. ..
  59. Ranchon F, Salles G, Späth H, Schwiertz V, Vantard N, Parat S, et al. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 2011;11:478 pubmed publisher
    ..Our findings point to the very small number of chemotherapy errors that actually reach patients, although problems in the chemotherapy ordering process are frequent, with the potential for being dangerous and costly. ..
  60. Locatelli Sanchez M, Couraud S, Arpin D, Riou R, Bringuier P, Souquet P. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 2013;191:491-9 pubmed publisher
    ..By contrast, exon 18 sensitizing mutations showed a worse PFS than exon 19 or 21 mutations. Finally, dose reduction was significantly more frequent in the erlotinib group than in the gefitinib group. ..
  61. Dumontet C, Jordan M. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790-803 pubmed publisher
    ..In the current search for novel microtubule-binding agents, enhanced tumour specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives. ..
  62. Cassier P, Labidi Galy S, Heudel P, Dutour A, Meeus P, Chelghoum M, et al. Therapeutic pipeline for soft-tissue sarcoma. Expert Opin Pharmacother. 2011;12:2479-91 pubmed publisher
    ..However, much remains to be done to improve our understanding of the molecular biology of this heterogeneous group of diseases. ..
  63. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay J, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12:673-80 pubmed publisher
    ..This combination cannot be recommended for first-line treatment in patients with metastatic renal cell carcinoma. French Ministry of Health and Wyeth Pharmaceuticals. ..
  64. Tagoug I, Plesa A, Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol. 2013;706:11-6 pubmed publisher
    ..These results suggest that bortezomib may influence the sensitivity of myeloma cells to soluble growth factors by down-regulation of membrane receptors...
  65. Cassier P, Castets M, Belhabri A, Vey N. Targeting apoptosis in acute myeloid leukaemia. Br J Cancer. 2017;117:1089-1098 pubmed publisher
    ..In this review, we discuss the current development of drugs designed to trigger cell death in AML...
  66. Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C, Tranchand B, et al. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol. 2003;14:615-22 pubmed
    ..Fotemustine as a single agent has definite activity in patients with relapsing or refractory multiple myeloma, with acceptable toxicity and can be administered at conventional doses in patients with mild or moderate renal impairment. ..
  67. Galmarini C, Jordheim L, Dumontet C. Pyrimidine nucleoside analogs in cancer treatment. Expert Rev Anticancer Ther. 2003;3:717-28 pubmed
    ..Strategies to optimize intracellular analog accumulation and to enhance cancer cell selectivity are proving beneficial in clinical trials. ..
  68. Valdameri G, Gauthier C, Terreux R, Kachadourian R, Day B, Winnischofer S, et al. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem. 2012;55:3193-200 pubmed publisher
    ..Finally, methoxy groups at positions 3, 4, and 5 of the B-ring markedly increased cytotoxicity and, therefore, should be avoided. ..
  69. Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther. 2012;12:685-95 pubmed publisher
    ..More recently, the molecular characterization of thymoma and thymic carcinoma led to the identification of potentially druggable targets, laying the foundations to implement personalized medicine for patients...
  70. Ghesquieres H, Cartron G, Seymour J, Delfau Larue M, Offner F, Soubeyran P, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 2012;120:2650-7 pubmed
    ..The PRIMA study is registered at as NCT00140582. ..
  71. Dalle S, Thomas L. Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate. Dermatol Clin. 2008;26 Suppl 1:39-41 pubmed
  72. Nicolini F, Basak G, Kim D, Olavarria E, Pinilla Ibarz J, Apperley J, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123:2875-2880 pubmed publisher
    ..The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo-SCT)...
  73. Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz J. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int. 2010;106:779-85 pubmed publisher
  74. Ray Coquard I, Pautier P, Pujade Lauraine E, Meeus P, Morice P, Treilleux I, et al. [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France]. Bull Cancer. 2010;97:123-35 pubmed publisher
    ..The other new scientific data concern surgical procedures for sex cords tumors, evidence for presence of FOXL2 mutation in adult granulosa cell tumors, the use of paclitaxel plus carboplatin for sex cords tumors...
  75. Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer. 2008;112:572-80 pubmed
    ..By using 2 simple parameters assessed at the time of diagnosis, the authors devised a prognostic system of immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices. ..
  76. Biston M, Joubert A, Charvet A, Balosso J, Foray N. In vitro and in vivo optimization of an anti-glioma modality based on synchrotron X-ray photoactivation of platinated drugs. Radiat Res. 2009;172:348-58 pubmed publisher
    ..The therapeutic benefit of anti-glioma synchrotron strategies appears to be correlated with the percentage of unrepaired DSBs but not with the number of DSBs induced. ..
  77. Nicolini F, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica. 2007;92:1238-41 pubmed
    ..Overall survival since IM initiation was 42.5 months for chronic, and 17.5 months for advanced phases, and all patients progressed. This mutation seems related to or (partially?) responsible for progression and poor survival. ..
  78. Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley L, Ambrosetti D, et al. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. Br J Cancer. 2017;117:947-953 pubmed publisher
    ..These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients. CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients. ..
  79. Mehlen P, Guenebeaud C. Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol. 2010;22:46-54 pubmed publisher